VC-backed Alarm.com files for IPO

Vienna, Virginia-based Alarm.com Holdings, a connected home platform solution, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on trading the stock on the NASDAQ under the ticker symbol “ALRM.” Goldman, Sachs & Co, Credit Suisse Securities LLC and BofA Merrill Lynch are serving as the lead underwriters. Alarm.com’s backers include ABS Capital and Technology Crossover Ventures.

162 Views

VC-backed Xactly files for IPO

San Jose, Calif.-based Xactly, a provider of sales performance management solutions, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. J.P. Morgan Securities LLC and Deutsche Bank AG Securities Inc will serve as the lead underwriters. The company’s backers include Alloy Ventures, Bay Partners, Glynn Capital Management, Outlook Ventures and Rembrandt Ventures.

101 Views

Fortress-owned FTAI debuts IPO

Fortress Transportation and Infrastructure Investors LLC, which owns and acquires transportation-related infrastructure and equipment, has raised $34 million for its IPO after pricing its 20 million shares at $17 per share. The stock began trading Friday on the NYSE under the ticker symbol “FTAI.” Citigroup Global Markets Inc., BofA Merrill Lynch, Barclays Capital Inc, Deutsche Bank Securities Inc and UBS Securities LLC are the lead underwriters. FTAI is owned by Fortress Investment Group.

VC-backed Arcadia Biosciences goes public

Davis, California-based Arcadia Biosciences, an agricultural products developer, has raised $65.6 million for its IPO after pricing its 8.2 million shares at $8 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “RKDA.” Credit Suisse Securities (USA) LLC and J.P. Morgan Securities LLC are the lead underwriters. Arcadia’s backers include Mandala Capital Limited, CMEA Capital, BASF Venture Capital and Saints Capital.

VC-backed Nivalis files for IPO

Boulder, Colorado-based Nivalis Therapeutics, a developer of drugs for patients with cystic fibrosis, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Nivalis plans on trading the stock on the NASDAQ under the ticker symbol “NVLS.” Cowen and Company and Stifel are serving as lead underwriters. The company’s backers include Apple Tree Partners, Deerfield, RA Capital, Rock Springs Capital and Wellington Management.

140 Views

VC-backed Glaukos Corp files for IPO

Laguna Hills, California-based Glaukos Corporation, a developer of treatments for glaucoma, has filed for an IPO. The number of shares that will be sold as well as the IPO’s pricing terms have yet to be set. The company plans on trading the stock on the NYSE under the ticker symbol “GKOS.” J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co are serving as the lead underwriters. Glaukos’ backers include OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Domain Associates, Fjord Ventures, Montreaux Equity Partners and Versant Ventures

PE HUB Community

Join the 12518 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget